Nuvalent (NASDAQ:NUVL) Insider Henry Pelish Sells 2,496 Shares

January 8, 2026 by InsiderTrades.com

Key Points

Nuvalent insider Henry Pelish sold 2,496 shares on Jan. 5 at an average price of $97.32 for $242,910.72, leaving him with 68,552 shares (a 3.51% reduction).
Multiple senior insiders—including CEO James R. Porter (sold 17,890 and 9,543 shares) as well as the CFO and several directors—executed substantial sales on Jan. 5–6, totaling several million dollars and signaling widespread insider selling.
Despite the insider sales, NUVL traded up about 9.9% to $106.82, has a market cap of $7.77 billion, and carries a consensus analyst rating of "Moderate Buy" with an average price target of $138.33.

Nuvalent, Inc. (NASDAQ:NUVL - Get Free Report) insider Henry Pelish sold 2,496 shares of the firm's stock in a transaction on Monday, January 5th. The stock was sold at an average price of $97.32, for a total transaction of $242,910.72. Following the completion of the sale, the insider owned 68,552 shares of the company's stock, valued at $6,671,480.64. The trade was a 3.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Nuvalent Trading Up 9.9%

Shares of NASDAQ NUVL opened at $106.82 on Thursday. The firm has a market capitalization of $7.77 billion, a P/E ratio of -20.08 and a beta of 1.32. The firm's 50-day moving average price is $102.64 and its 200-day moving average price is $88.91. Nuvalent, Inc. has a 1-year low of $55.53 and a 1-year high of $112.88.

Nuvalent (NASDAQ:NUVL - Get Free Report) last issued its earnings results on Thursday, October 30th. The company reported ($1.70) EPS for the quarter, missing analysts' consensus estimates of ($1.39) by ($0.31). During the same quarter last year, the company earned ($1.28) earnings per share. Equities research analysts forecast that Nuvalent, Inc. will post -3.86 EPS for the current year.

More Nuvalent News

Here are the key news stories impacting Nuvalent this week:

Negative Sentiment: CEO James R. Porter sold 17,890 shares on Jan. 5 at an average $97.32 for $1.741M (ownership down ~5.85%). SEC Filing
Negative Sentiment: CEO James R. Porter sold an additional 9,543 shares on Jan. 6 at ~$97.16 for $927k (ownership down ~3.31% after the sale). SEC Filing
Negative Sentiment: CFO Alexandra Balcom sold 4,236 shares on Jan. 5 at $97.32 (~$412k) and 3,181 shares on Jan. 6 at $97.16 (~$309k), reducing her stake by ~4.75% and ~3.75% respectively. SEC Filing
Negative Sentiment: Director/insider Christopher D. Turner sold 4,236 shares on Jan. 5 and 3,181 shares on Jan. 6 at ~ $97.32 / $97.16, cutting his stake by roughly 6.8% and 5.5%. SEC Filing
Negative Sentiment: Insider Deborah A. Miller sold 4,363 shares on Jan. 5 (~$424.6k) and 2,589 shares on Jan. 6 (~$251.5k), reducing her position by ~8.9% and ~5.8%. SEC Filing
Negative Sentiment: Insider Henry E. Pelish sold 2,496 shares on Jan. 5 (~$242.9k) and 2,664 shares on Jan. 6 (~$258.9k), trimming his stake by ~3.5% and ~3.9%. SEC Filing

Institutional Investors Weigh In On Nuvalent

Several large investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC raised its holdings in shares of Nuvalent by 47.6% in the 4th quarter. GAMMA Investing LLC now owns 335 shares of the company's stock valued at $34,000 after acquiring an additional 108 shares in the last quarter. Aster Capital Management DIFC Ltd purchased a new position in Nuvalent in the third quarter worth $38,000. Eastern Bank purchased a new position in Nuvalent in the third quarter worth $52,000. Persistent Asset Partners Ltd bought a new position in Nuvalent in the second quarter valued at $88,000. Finally, Farther Finance Advisors LLC increased its stake in Nuvalent by 9,230.8% in the second quarter. Farther Finance Advisors LLC now owns 1,213 shares of the company's stock valued at $93,000 after acquiring an additional 1,200 shares during the last quarter. Institutional investors own 97.26% of the company's stock.

Analysts Set New Price Targets

NUVL has been the subject of a number of recent research reports. Cantor Fitzgerald began coverage on shares of Nuvalent in a research note on Wednesday, October 15th. They set an "overweight" rating and a $135.00 price target for the company. Leerink Partners boosted their target price on shares of Nuvalent from $140.00 to $149.00 and gave the stock an "outperform" rating in a research report on Monday, November 17th. Robert W. Baird upped their target price on shares of Nuvalent from $112.00 to $158.00 and gave the stock an "outperform" rating in a report on Tuesday, November 18th. The Goldman Sachs Group lifted their price objective on shares of Nuvalent from $120.00 to $135.00 and gave the stock a "buy" rating in a report on Tuesday, November 18th. Finally, Truist Financial set a $140.00 price target on Nuvalent in a research report on Monday, November 24th. Fifteen investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Nuvalent has an average rating of "Moderate Buy" and a consensus target price of $138.33.

Get Our Latest Stock Analysis on Nuvalent

Nuvalent Company Profile

(Get Free Report)

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company's research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent's lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.